MedTrace Logo

Acamprosate in the Treatment of Pathological Gambling

NCT00571103 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-05-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see whether acamprosate (Campral) will curb the desire to gamble in people with pathological gambling disorder.

Conditions

  • Pathological Gambling

Interventions

DRUG

acamprosate

Two 333mg tablets taken three times daily.

Sponsors & Collaborators

  • University of Nebraska

    collaborator OTHER

  • Forest Laboratories

    collaborator INDUSTRY

  • University of Iowa

    lead OTHER

Principal Investigators

  • Donald W Black, MD · The University of Iowa Carver College of Medicine

  • Dennis P McNeilly, PsyD · University of Nebraska

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-07-31
Completion
2009-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00571103 on ClinicalTrials.gov